(redirected from 566C80)
Also found in: Medical.


A drug, C22H19ClO3, used to treat pneumonia caused by pneumocystis fungi and, in combination with proguanil, to prevent or treat malaria.

[Perhaps rearrangement of the letters of Aōt(us), night monkey genus on which testing was carried out during the development of atovaquone (Greek a-, without; see a-1 + ous, ōt-,, ear (from the small external ears of night monkeys); see otic) + (par)vaquone, veterinary drug chemically related to atovaquone (parva, specific epithet of Theileria parva, apicomplexan cattle pathogen against which parvaquone is effective, from Latin parva, feminine of parvus, small (from the relatively small size of the pathogen); see pau- in Indo-European roots) + qu(in)one.]


n atovacuona
Mentioned in ?
References in periodicals archive ?
Studies reported herein have demonstrated 566C80 to be a potent and selective mitochondrial inhibitor with mitochondria isolated from Plasmodium falciparum and Plasmodium yoelii (Hudson 1991).
In the last five years, Georgetown's clinical research program has examined such issues as single and combination antiretroviral therapies, such as AZT alone or in combination with ddI, ddC, or acyclovir, and treatment strategies for major opportunistic infections including a study of 566C80 in the treatment of pneumocystis carinii pneumonia.